ArticleNeoplasia (New York, N.Y.)2026
Inhibitory effects of c-MYC degrading rLON protease on intestinal polyps in PIRC rat, a familial adenomatous polyposis model.
Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide, accounting for approximately 10% of all cases, and is the second leading cause of cancer-related deaths in the United States. In patients with Familial Adenomatous Polyposis (FAP), APC mutations drive c-MYC overexpression, promoting metabolic and immune dysregulation that contributes to CRC development, making c-MYC a potential target for FAP-associated chemoprevention. Although no c-MYC inhibitors are currently available, recent evidence indicates that a uropathogenic E. coli protease can degrade c-MYC protein. This study evaluated recombinant LON protease (rLONP) for chemopreventive efficacy in PIRC rats, a model of FAP. Rat pups were genotyped, baseline polyp burden was established by colonoscopy, and animals were randomized to receive saline or rLONP twice daily (2.5 mg/kg, p.o.) for 2 or 4 weeks. Serum analyses showed no significant changes in liver or kidney function markers in rLONP-treated rats compared with controls. rLONP-treated male rats exhibited a ∼40% reduction in colonic polyps at both time points, and small intestinal polyp counts were also lower in treated males and females. Combined analysis demonstrated a ≥60% reduction in total intestinal polyp multiplicity after 2-4 weeks of treatment (p<0.001). Protein expression analyses of colonic polyps revealed decreased c-MYC protein levels following rLONP treatment. Immunohistochemistry further showed reduced Ki-67, Cyclin D1, and c-MYC expression in treated polyps compared with controls. Overall, rLONP was well tolerated and significantly reduced intestinal polyp burden in PIRC rats in this short-term study, supporting further long-term efficacy evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.